Short Interest in Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) Drops By 46.1%

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) saw a significant decrease in short interest in February. As of February 15th, there was short interest totalling 10,400 shares, a decrease of 46.1% from the January 31st total of 19,300 shares. Based on an average daily volume of 2,030,000 shares, the short-interest ratio is presently 0.0 days. Approximately 0.7% of the shares of the stock are sold short.

Salarius Pharmaceuticals Price Performance

Shares of NASDAQ SLRX opened at $1.08 on Friday. The firm’s 50-day moving average is $1.93 and its two-hundred day moving average is $1.70. The company has a market capitalization of $1.71 million, a PE ratio of -0.13 and a beta of 0.84. Salarius Pharmaceuticals has a 12-month low of $0.91 and a 12-month high of $7.20.

Salarius Pharmaceuticals Company Profile

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma.